ArticleESMO open2026
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeptomeningeal metastases (LM) in epidermal growth factor receptor mutant (EGFRm) non-small-cell lung cancer (NSCLC) represent a major therapeutic challenge. Despite the improved central nervous system penetration of third-generation EGFR tyrosine kinase inhibitors (TKIs), key uncertainties persist regarding the efficacy of combination regimens with antiangiogenic therapy and intrathecal chemotherapy and optimal dosing because of the limited evidence. PATIENTS AND
methodsIn this large-scale, multicenter, retrospective study, 618 patients with EGFRm NSCLC and LM who were treated with furmonertinib-based regimens between March 2021 and December 2024 were enrolled. The primary endpoint was overall survival (OS). Secondary endpoints included OS from LM diagnosis (LMOS), time to treatment failure (TTF), clinical response rate (CRR), LM-specific objective response rate (ORR-LM), and treatment-related adverse events (TRAEs).
resultsThe median OS was 14.19 months [95% confidence interval (CI) 13.04-16.79], median LMOS was 17.05 months (95% CI 14.81-19.22), and median TTF was 11.23 months (95% CI 10.23-12.13). Triple therapy (furmonertinib plus antiangiogenic therapy and chemotherapy) was associated with longer median OS than mono or dual regimens (17.91 versus 10.31-14.19 months, P < 0.001). Notably, among patients with prior third-generation EGFR-TKI exposure, triplet therapy achieved a median OS of 17.18 months. In patients with poor performance status (Eastern Cooperative Oncology Group score 3-4), triplet therapy showed markedly improved OS compared with other regimens (17.31 versus 9.02-12.81 months, P = 0.003). Regarding furmonertinib dosing, 80 mg/day and 160 mg/day were associated with longer OS than 240 mg/day (16.79/14.68 versus 11.39 months, P = 0.002). The CRR was 66.7%, and the ORR-LM was 40.6%. TRAEs occurred in 59.2% of patients, with grade 3-4 events reported in 7.9%.
conclusionsThis large real-world study suggests that furmonertinib-based therapy, particularly the triplet regimen with antiangiogenic agent and chemotherapy, is associated with meaningful clinical outcomes over mono or dual therapy in patients with EGFRm NSCLC and LM, including those with prior third-generation TKI resistance or poor performance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.